%1

About two thirds of the New Zealand female population are either overweight (Body Mass Index, BMI 25 – 29) or obese (BMI 30 or more). The figures for women with breast cancer are similar.

“After 100 years, we need to do something” is how Dr Sunil Lakhani summed up a session on lobular breast cancer at Breast Cancer Trials’ recent scientific meeting (Brisbane, July

Medical oncologists from New Zealand and Australia met recently in Brisbane to discuss research progress with oral SERDs (selective oestrogen receptor degraders) for treating hormone receptor posit

Breast cancer patients prescribed SSRIs (selective serotonin reuptake inhibitors, such as citalopram, escitalopram, fluoxetine, paroxetine or sertraline) to help with anxiety and depression after d

Even after six decades of silicone, “every implant fails eventually” according to Australian plastic and reconstructive surgeon Dr Michael Wagels who spoke at Breast Cancer Trials’ recent Annual Sc

The current state of play in developing liquid biopsies for breast cancer was described at Breast Cancer Trials’ Annual Scientific Meeting in Hobart by Professor Sarah-Jane Dawson from the Peter Ma

At the recent Breast Cancer Trials Annual Scientific Meeting in Hobart Professor Shelley Potter from Bristol presented results from the ANTHEM study.

CDK4/6 inhibitors, palbociclib, ribociclib and abemaciclib, are important medicines for treating hormone receptor (HR) positive breast cancer, especially after tumours have become resistant to endo

Australian doctors Belinda Yeo and Virginia Baird gave a very enlightening and frank presentation on sexual health at Breast Cancer Trials’ recent conference in Hobart, with some excellent advice n

The fear of recurrence is something that most people who have been treated for cancer experience, but it is often the ‘elephant in the room’ when patients meet with their doctors.